A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients

Table 2

Measurement of median (min; max) HCV viral load at month 12 in patients completing the study*.

	N	TAC/DAC	N	TAC/STR
Median (min; max) HCV viral load, IU/mL; PAS	19	5.46 (0.95; 6.54)	35	5.91 (0.95; 6.89)
Median (min; max) HCV viral load, IU/mL; PAS (no viral) treatment during study	14	5.77 (3.45; 6.54)	20	5.99 (5.32; 6.89)
Median (min; max) HCV viral load, IU/mL; FAS	25	4.52 (0.95; 6.4)	46	5.9 (0.95; 6.89)
Median (min; max) HCV viral load, IU/mL; FAS (no viral) treatment during study	20	5.25 (0.95; 6.54)^†	26	5.99 (3.47; 6.89)

PAS: Primary analysis set: All randomized and transplanted subjects with baseline viral load above the limit of quantification.
FAS: Full analysis set: All randomized and transplanted patients
*Patients completing the study with data available within ± 14 days of day 365.
^†𝑃=0.024 Wilcoxon rank sum test for superiority of TAC/DAC over TAC/STR.